We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CDRH on Target to Complete PMA Code Review This Year

CDRH on Target to Complete PMA Code Review This Year

May 1, 2015

CDRH has reviewed 69 percent of PMA products approved before 2010 — exceeding its 2014 target — as it works to implement a goal of speeding new technologies to patients without compromising safety.

Under its 2014-2015 strategic goal of balancing premarket and postmarket data collection during the premarket application review, CDRH aimed to review half of those product codes by the end of last year. PMA codes created since 2010 weren’t included because the device center needs more information on postmarket performance of these devices before evaluating them for a change in classification or data collection requirements, CDRH says.

In a retrospective review published April 29, CDRH listed 42 product codes identified as candidates for reclassification, three that were reclassified in 2014 and 96 expected to remain unchanged.

The list includes 21 codes for products considered candidates for reclassification into Class II, such as cervical dilators, certain laser and testicular hypothermia devices. Codes were placed in this category if it was determined that special controls would suffice to provide reasonable assurance of safety, CDRH says.

Another 21 codes were determined to be candidates for reduced premarket data and greater reliance on postmarket controls or data collection.

Products under these codes include silicone gel-filled breast prostheses, cervical cytology slide processors and radionuclide microspheres.

Ninety-six codes — including pacemakers and heart valves, intraspinal catheters, cochlear implants, multifocal intraocular lenses, hip prostheses and glucose sensors — should remain in Class III with no changes to data collection, CDRH says.

CDRH is working to have 75 percent of product codes reviewed by June 30 and 100 percent by the end of the year. Once that is done, the FDA will prioritize candidates for reclassification and for change in data collection to determine how to ensure the greatest impact, the review says.

The review follows the release of two guidances by CDRH and the Center for Biologics Evaluation and Research last month on balancing premarket and postmarket data collection for devices and expedited access to devices for patients with life-threatening or irreversibly debilitating conditions.

CDRH seeks public comment until June 29 on the product codes it has reviewed. Read the guidance at www.fdanews.com/04-28-15-Pre
market.pdf
. — Charlotte Astor

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing